The collaboration leverages uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing and regulatory support.
GERMANTOWN, MD / ACCESS Newswire / March 30, 2026 /uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) development ...
GERMANTOWN, MD / ACCESS Newswire / March 30, 2026 / uBriGene Biosciences, a leading global CDMO specializing in lentiviral vector manufacturing and Advanced Therapy Medicinal Product (ATMP) developmen ...
A life sciences firm appoints a new board chair to strengthen governance, support global expansion, and guide growth in biomolecule quantification as demand rises across biologics research, ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced a 30-minute oral presentation on TG4050, the ...
Google thinks it's found the answer, and it doesn't require more or better hardware. Originally detailed in an April 2025 ...
About Addgene Addgene is a purpose-driven organization committed to accelerating discovery and innovation by helping scientists conduct experiments with greater ease, speed, and r ...
Oxford BioMedica PLC (OXBDF) reports a 33% revenue increase and achieves profitability, while expanding its US commercial ...
Oxford BioMedica reported preliminary 2025 revenue of £168.70 million, a 33% increase that exceeded the consensus estimate of £166.22 million from eight analysts ...
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its man ...
Liu said adding the two diseases in Category B reflects two main considerations: strengthening preparedness against the risk ...
Moltbook launched in January 2026 as a Reddit-style platform for OpenClaw AI agents. Meta acquired it six weeks later. Here's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results